ReviewDrug design, development and therapy2020
Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.
Review in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Pregnancy and COVID-19: high or low risk of vertical transmission.Clinical and experimental medicine · 2023Pooled it
- Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis.BMC pregnancy and childbirth · 2021Pooled it
- Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review.Frontiers in medicine · 2021Pooled it
- Timing-specific efficacy of antiviral baloxavir and anti-inflammatory oclacitinib monotherapies, and the benefits of their combination in treating influenza in mice.Frontiers in microbiology · 2026Article
- Persistent hepatocyte secretory failure in lopinavir/ritonavir related to drug-induced liver injury: a case report.Frontiers in medicine · 2025Article
- Safety and Tolerability of Antimicrobial Agents in the Older Patient.Drugs & aging · 2023Review
- Molecular and Physiological Aspects of SARS-CoV-2 Infection in Women and Pregnancy.Frontiers in global women's health · 2022Review
- Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management.Frontiers in pharmacology · 2022Review
- Maternal and Neonatal Outcomes of Critically Ill Pregnant and Puerperal Patients Diagnosed with COVID-19 Disease: Retrospective Comparative Study.Journal of Korean medical science · 2021Observational
- Pharmacological Treatments against COVID-19 in Pregnant Women.Journal of clinical medicine · 2021Review
- Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver.Journal of clinical and translational hepatology · 2021Review
- Management and Prevention of COVID-19 in Pregnancy and Pandemic Obstetric Care: A Review of Current Practices.Healthcare (Basel, Switzerland) · 2021Review
- Potent phytochemicals against COVID-19 infection from phyto-materials used as antivirals in complementary medicines: a review.Future journal of pharmaceutical sciences · 2021Review
- Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective.World journal of gastroenterology · 2020Review
- COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics.Pharmaceutics · 2020Review
- SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.Annals of clinical microbiology and antimicrobials · 2020Review
- Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database.Infection and drug resistance · 2020Article
- COVID-19 and Pregnancy.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.